#United States #New York #Class Action #Pomerantz LLP #Hims & Hers

Introduction

In a significant development for investors of Hims & Hers Health, Inc. (NYSD: HIMS), Pomerantz LLP has launched a class action lawsuit, prompting immediate action from affected shareholders. Investors who purchased or acquired Hims & Hers stocks are advised to act promptly as they may have the right to join the lawsuit and potentially seek restitution for their losses.

Background of the Lawsuit

The legal action stems from allegations that Hims & Hers and certain of its executives engaged in securities fraud and other unlawful business practices, undermining investor trust and violating securities laws. The period of concern for the class action spans from [start date] to [end date], and shareholders are encouraged to verify their eligibility for participation.

Those interested in being appointed as the Lead Plaintiff must submit their request to the court by August 25, 2025, allowing the opportunity for some shareholders to lead the case against the company’s management. A detailed copy of the class action complaint can be accessed through Pomerantz's website.

Recent Developments

Investors were alarmed when news broke about Hims & Hers' long-term collaboration with Novo Nordisk, introduced on April 29, 2025. The partnership aimed to promote Wegovy®, a product approved by the FDA, through Hims & Hers' platform. However, a series of unfortunate events unfolded.

On June 23, 2025, fewer than two months after the collaboration announcement, Novo Nordisk publicly severed ties with Hims & Hers. The company cited deceptive promotional practices and expressed concern over patient safety related to the sale of unauthorized versions of their product. The announcement culminated with reports that the active pharmaceutical ingredients in these illegitimate products were sourced from unapproved entities, posing potential risks to consumers.

This controversy dramatically impacted Hims & Hers' stock performance, with shares plummeting 34.63% to close at $41.98 the same day Novo Nordisk announced the termination. This drop represents a troubling financial landscape for investors who may find themselves increasingly concerned about the company’s future and litigation risk.

The Role of Pomerantz LLP

Pomerantz LLP is highly regarded in the arena of corporate and securities class litigation, known for its robust legal framework founded by industry pioneer Abraham L. Pomerantz. The firm’s 85-year history includes extensive recoveries for victims of securities fraud and corporate abuse. By conducting this investigation and organizing a class action, Pomerantz aims to protect investors' interests and hold companies accountable for any misconduct.

Those with inquiries about the lawsuit or interested in participating can contact Danielle Peyton at either podirector's email or telephone number, which has been provided for convenience. Furthermore, investors should be prepared to furnish key details, including their mailing address and number of shares purchased, to streamline the process.

Conclusion

In light of this class action lawsuit involving Hims & Hers Health, Inc., investors are urged to assess their positions and determine whether they’re eligible to join this significant legal matter. Keeping abreast of deadlines such as August 25, 2025, and remaining in touch with legal representatives from Pomerantz LLP can provide the necessary guidance and resources for those looking to navigate this complex situation. Protecting investments and getting clarity in volatile market scenarios is more crucial than ever, and class actions are often a valuable recourse for aggrieved shareholders.

For continued updates and information regarding this case, interested parties can refer to Pomerantz Law Firm's official site or reach out through the provided contact details.

• ---